CSIMarket
 
Astrazeneca Plc  (AZN)
Other Ticker:  
 
 
Price: $65.8500 $-0.46 -0.694%
Day's High: $66.37 Week Perf: -2.3 %
Day's Low: $ 65.81 30 Day Perf: 4.79 %
Volume (M): 3,887 52 Wk High: $ 76.56
Volume (M$): $ 255,933 52 Wk Avg: $68.30
Open: $66.01 52 Wk Low: $60.47



 Market Capitalization (Millions $) 102,858
 Shares Outstanding (Millions) 1,562
 Employees 76,100
 Revenues (TTM) (Millions $) 45,811
 Net Income (TTM) (Millions $) 5,961
 Cash Flow (TTM) (Millions $) 5,840
 Capital Exp. (TTM) (Millions $) 1,361

Astrazeneca Plc
AstraZeneca Plc is a global pharmaceutical and biopharmaceutical company, headquartered in Cambridge, England, with research and development centers in Sweden, the United States and China. It is one of the largest pharmaceutical companies in the world and operates in over 100 countries.

The company was formed in 1999 through the merger of two established pharmaceutical companies, Astra AB of Sweden and Zeneca Group plc of the UK. AstraZeneca specializes in the development and marketing of prescription drugs for a variety of medical conditions, including cardiovascular, respiratory, and oncology diseases, among others.

AstraZeneca has a strong commitment to innovation, with a significant portion of its revenue reinvested into research and development. It operates several research and development centers worldwide, focusing on therapeutic areas that include oncology, respiratory, and cardiovascular disease. The company's research and development efforts have led to the development of a wide range of life-saving drugs, such as Seloken, Atacand, Crestor, Symbicort, and Imfinzi.

AstraZeneca is also committed to sustainability and to providing a positive impact on the environment and society. The company operates with a strong emphasis on environmental responsibility and sustainability, working towards the reduction of greenhouse gas emissions, water conservation, and responsible waste management. The company is also committed to providing access to affordable medicines to underserved populations.

In 2020, AstraZeneca became a household name due to its success in developing a vaccine for COVID-19 in collaboration with the University of Oxford. The vaccine, which requires two doses, has been authorized in many countries around the world and is playing a crucial role in the global fight against the pandemic.

AstraZeneca is publicly traded on the London Stock Exchange and is a constituent of the FTSE 100 index. It is currently led by CEO Pascal Soriot. As of 2021, the company had approximately 76,100 employees worldwide and reported revenue of $26.6 billion.


   Company Address: 1 Francis Crick Avenue Cambridge 0
   Company Phone Number: 3749 5000   Stock Exchange / Ticker: NASDAQ AZN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Astrazeneca Plc

AstraZeneca Plc Sees Incredible 80.57% Income Surge in Q4 of 2023

AstraZeneca Plc, a major pharmaceutical preparations company, has recently reported some impressive profitability results for the October to December 31, 2023 interval. The company saw its income per share increase by a significant 80.57%, reaching $3.81 per share. This sharp increase in earnings per share is certainly good news for investors as it indicates strong performance and growth potential.
In addition to the impressive increase in income per share, AstraZeneca also saw a modest 3.29% rise in revenue to $45.81 billion during the same reporting period. This marks a positive trend for the company as it continues to grow its top-line figures. Comparing these results to the same reporting period a year prior, where revenue was at $0.00 million, it is clear that AstraZeneca has made significant strides in expanding its business and generating revenue.






 

Astrazeneca Plc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Astrazeneca Plc does not provide revenue guidance.

Earnings Outlook
Astrazeneca Plc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com